Clinical Trial Update: A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating the combination of docetaxel and carboplatin in patients with hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED